Short seller convicted of fraud after boasting ‘it’s like taking candy from a baby’ The investor took to social media after the verdict, writing, ‘This is not over’ The Independent UK · Jun 2
Short seller Andrew Left convicted of securities fraud A federal grand jury in California has convicted short seller Andrew Left of securities fraud AAP · Jun 2
Who Is Andrew Left? Wall Street's Prominent Short Seller Found Guilty Of Fraud, May Face Jail Time Andrew Left, founder of Citron Research, was found guilty of securities fraud, accused of manipulating stocks and defrauding investors, potentially facing 45 years in prison. International Business Times UK · Jun 2
Citron Research Is Betting Against Sandisk Stock. Should You? Citron Research has issued a new short report on Sandisk. Barchart · Mar 4
Sandisk Stock Hype Could ‘Vanish in a Single Earnings Call’ According to Citron Research. Is It Time to Ditch SNDK Here? After a 1,200% surge and a blistering earnings rebound, Sandisk stock now faces rising skepticism that the NAND boom may already be peaking. Barchart · Mar 3
Long Bitcoin, Short MicroStrategy: Citron Research 'Proud Of The Timing' One Year Later Short seller Citron Research, led by Andrew Left, made a prediction one year ago. The firm bet on Bitcoin (CRYPTO: BTC), but against the Bitcoin treasury company Strategy Inc (NASDAQ:MSTR). Here are the results of the trade. Benzinga · Nov 21, 2025
Trump Just Made This The 'Most Important Company In America,' Says Andrew Left: 'That Nobody's Heard Of...' Andrew Left’s Citron Research is calling out a little-known nuclear contractor, which it says is about to become one of the most strategically significant companies in the United States under the Trump administration. Benzinga · Nov 20, 2025
Nvidia Hits $5 Trillion: Is This The Next Dot-Com Bubble Or AI Gold Rush? The 56x Return Investor Speaks As chipmaker NVIDIA Corp. (NASDAQ:NVDA) surges past $5 trillion in market capitalization, several prominent analysts have reacted to the stock’s unrelenting rally, amid growing concerns regarding its sustainability and speculations of an AI bubble. Benzinga · Oct 30, 2025
What's Going On With Bleichroeder Acquisition Corp (BACQ) Stock Today? Bleichroeder Acquisition Corp (NASDAQ:BACQ) shares are trending higher Thursday following commentary from Citron Research highlighting the SPAC’s risk-reward profile. Benzinga · Oct 23, 2025
Rigetti Vs. Infleqtion: Citron Weighs In On Quantum 'Raging Bulls' Citron Research's assessment of Rigetti Computing Inc. (NASDAQ:RGTI) versus Infleqtion, the quantum technology firm set to merge with Churchill Capital Corp X (NASDAQ:CCCX), has "raging" quantum bulls locking horns. Benzinga · Oct 9, 2025
Teladoc (TDOC) Shares Climb On Bullish Commentary From Citron Research Shares of Teladoc Health Inc (NYSE:TDOC) are surging Friday morning after Citron Research posted bullish comments on the telehealth provider, asserting they were “not wrong, just early” on the stock’s potential. The commentary sparked renewed investor interest, pushing the stock higher in early trading. Benzinga · Oct 3, 2025
Cardlytics Stock Surges 5% After Hours As Citron Research Spotlights Wells Fargo Partnership Cardlytics Inc. (NASDAQ: CDLX) saw its stock fall 9.85% during regular trading on Thursday. However, the stock rebounded in after-hours trading, climbing 5.04% to $2.50 following positive remarks from analysts. Benzinga · Sep 26, 2025
Cardlytics Stock Soars After Citron Research Says Shares Could 'Double Or Triple' From Here Shares of Cardlytics, Inc. (NASDAQ:CDLX) are rising on Wednesday after a research firm published a glowing report on the company, which partners with retail outlets and banks to offer cash-back rewards on card purchases. Benzinga · Sep 24, 2025
Cardlytics (CDLX) Stock Soars Over 50% On AmEx News And Citron Tweet Shares of advertising-platform Cardlytics Inc (NASDAQ:CDLX) are surging Thursday morning. The rally was ignited by a bullish tweet from Citron Research connecting Cardlytics to news of the American Express Co (NYSE:AXP) Platinum card refresh. Benzinga · Sep 18, 2025
Benzinga · Sep 17, 2025 Pharma Bro Martin Shkreli Confirms Shorting Opendoor, Plans Public Due Diligence Campaign Into The Firm: 'I Shorted $OPEN' Martin Shkreli, also popularly known as ‘Pharma Bro,’ announced late Tuesday that he has taken a short position against iBuying real estate company Opendoor Technologies Inc. (NASDAQ:OPEN).
Benzinga · Sep 14, 2025 Elon Musk's Two-Word Response, Trump Administration's Patent Share, Palantir CEO's China Warning And More: This Week In Politics It’s been an eventful week, with some of the most influential figures in the business world making headlines. Here’s a quick recap of the top political stories you might have missed.
Benzinga · Sep 9, 2025 Trump-Linked Mortgage Trade? Citron Says This Stock Is A Soldier In 'War On Housing' — Predicts 91% Upside Andrew Left’s Citron Research is making a bold new bet in the housing finance space, framing it as a deep-value play, and one that is likely to play a central role in President Donald Trump’s new housing policy.
Benzinga · Sep 9, 2025 Short Seller Andrew Left Recalls Bet On Nebius As It Soars Over 130% In 2025: 'Just A Pat On The Back' From When NBIS Was At $20 Per Share Famed short-seller Andrew Left of Citron Research is taking a victory lap on a bullish call, celebrating his firm’s early bet on AI infrastructure company Nebius Group NV (NASDAQ:NBIS).
Benzinga · Sep 9, 2025 Martin Shkreli Doubles Down On Opendoor 'Short' Call: 'Pharma-Bro' Draws Parallels With Newegg — 'Game Over Losers' Former hedge fund manager and pharmaceutical executive, Martin Shkreli, doubled down on his bearish stance against Opendoor Technologies Inc. (NASDAQ:OPEN), drawing parallels with another retail favorite stock that has since witnessed a pullback.
Benzinga · Sep 5, 2025 Opendoor Attacked By Short Seller—Stock Pops Anyway Citron Research, led by famed short-seller Andrew Left, targeted Opendoor Technologies, Inc. (NASDAQ:OPEN) in a social media post on Friday. Opendoor investors shrugged off the attack, and the stock climbed.
Benzinga · Aug 25, 2025 Palantir's AI Edge: PEG Ratio Outshines Salesforce—'Sleeper Valuation' Defying P/E Skeptics? In a landscape where high Price-to-Earnings (P/E) ratios often scare investors, a different metric defies skeptics that AI powerhouse, Palantir Technologies Inc. (NASDAQ:PLTR), which was battered last week for its high valuations following a Citron Research report, is not quite overpriced.
Benzinga · Aug 22, 2025 Palantir's 70x Revenue Valuation May Be Unsustainable Despite 'Outstanding Q2 Results' — Citi Analyst Warns Company's 'Edge' May Fade As AI Expands According to Tyler Radke, a senior Citigroup equity analyst, Palantir Technologies Inc.’s (NASDAQ:PLTR) lofty valuations are difficult to justify despite its “outstanding Q2 results.”
Benzinga · Aug 20, 2025 Palantir Short Seller Andrew Left's Citron Now Compares It To Databricks: 'PLTR Is A $40 Stock, And Every Real AI Leader Keeps Reminding Us' Short-seller Andrew Left‘s Citron Research intensified its campaign against Palantir Technologies Inc. (NYSE:PLTR) on Wednesday, posting a direct comparison to private competitor Databricks that highlights Palantir’s slower growth on several key metrics.
Benzinga · Aug 20, 2025 Palantir Continues To Decline In Pre-Market As Valuation Concerns Mount—Citron Research Targets Overvaluation Palantir Technologies Inc. (NASDAQ:PLTR) declined 0.95% to $156.08 during pre-market on Wednesday, extending its 9.35% drop from Tuesday's regular trading, despite expanding its partnership with Fujitsu Ltd.
Benzinga · Aug 19, 2025 Palantir Stock Is Trending Tuesday: What's Going On? Palantir Technologies Inc (NASDAQ:PLTR) is trading lower on Tuesday as selling pressure and weaker momentum indicators weighed on investor sentiment. Valued at $412 billion, Palantir’s market cap has soared despite generating only $1.7 billion in free cash flow, making it appear as though it has “invented time travel” in the…